Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 482 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizo Affective Disorder Clear all
Completed Phase 2 Interventional Results available

Reducing Internalized Stigma in People With Serious Mental Illness

NCT01259427
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
Interventions
Ending Self Stigma (ESS), Health and Wellness Group
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Jun 10, 2026, 3:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT02149823
View directory record Official record
Conditions
Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD, Autism Spectrum Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo
Drug
Lead sponsor
Maria de las Mercedes Perez Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Phase 4 Interventional

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

NCT00320723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
bupropion, transdermal nicotine patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Results available

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View directory record Official record
Conditions
Patient Noncompliance
Interventions
haloperidol decanoate, haloperidol, Customized Adherence Enhancement
Drug · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Jun 10, 2026, 3:04 PM EDT
Active, not recruiting Not applicable Interventional

Young Adults With Violent Behavior During Early Psychosis (Aim 2)

NCT05756855
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder, Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
adapted behavioral intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
16 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Appeal and Impact of E-cigarettes in Smokers With SMI

NCT03050853
View directory record Official record
Conditions
Tobacco Dependence, Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
E-cigarette
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Louisville, Kentucky • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional

Academic-Community EPINET (AC-EPINET)

NCT04497857
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 10, 2026, 3:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Targeting Individual Alpha Frequencies to Enhance Perceptual Timing

NCT04856657
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder
Interventions
Transcranial alternating current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Results available

Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers

NCT02386605
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Results available

Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

NCT00288366
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional

Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode

NCT02823041
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive Training, Aerobic Exercise, Case management and supportive psychotherapy, Individual Placement and Support
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

NCT01143077
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Phase 2 Interventional Results available

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

NCT00690274
View directory record Official record
Conditions
Schizophrenia
Interventions
BF2.649, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Results available

Brain Stimulation and Cognitive Training

NCT03338673
View directory record Official record
Conditions
Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
Interventions
tDCS, BrainHQ
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Results available

Remediation of Working Memory in Schizophrenia

NCT00995553
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation, Computer Skills
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Jun 10, 2026, 3:04 PM EDT
Recruiting No phase listed Observational

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jun 10, 2026, 3:04 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia

NCT00338975
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Behavioral Social Skills Training (CBSST), Goal-focused supportive contact (GFSC), Social Skills Training, Goal Setting
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional

A Comparative Study of New Medications for Psychosis in Adolescents

NCT00222495
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions
quetiapine, olanzapine, risperidone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Results available

Omega-3 Dietary Supplements in Schizophrenia

NCT01786239
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
Interventions
Risperidone, Omega-3 capsules, Placebo
Drug
Lead sponsor
Delbert Robinson
Other
Eligibility
15 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional

Personalized and Scalable Cognitive Remediation Approaches

NCT01945333
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive remediation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Brooklyn, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Texting for Relapse Prevention

NCT02819349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Texting for Relapse Prevention (T4RP)
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jun 10, 2026, 3:04 PM EDT
Completed Phase 4 Interventional

Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder

NCT00501618
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Fazaclo
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jun 10, 2026, 3:04 PM EDT